| Literature DB >> 34051865 |
Bao-Shi Fan1,2,3, Yang Liu1,2, Ji-Ying Zhang1,2, You-Rong Chen1,2, Meng Yang1,2,3, Jia-Kuo Yu4,5.
Abstract
BACKGROUND: The stem cells of the stem cell banks have prominent problems for insufficient sources, easy contamination, unstable biological characteristics after serial subcultivations, and high cost.Entities:
Keywords: Basic principle; Stem cell; Stem cell bank; Tissue-engineered cartilage; Tissue-engineered ligament; Tissue-engineered meniscus
Mesh:
Year: 2021 PMID: 34051865 PMCID: PMC8164236 DOI: 10.1186/s13287-021-02360-3
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 6.832
The famous stem cell bank established in the world
| Name of bank | Stem cell type | Country | Website and/or reference |
|---|---|---|---|
| UK Stem Cell Bank | Comprehensive | UK | |
| National Centre for Cell Science Cell Repository | Comprehensive | USA | |
| WiCell International Stem Cell Bank | Comprehensive | USA | |
| Cord Blood Registry | Cord blood/cord tissue stem cells | USA | |
| Australian Cord Blood Bank | Cord blood | Australia | |
| BioEden | Child milk tooth stem cells | USA | |
| Human Pluripotent Stem Cell Registry | Human pluripotent stem cell | Global registry | |
| Swiss Stem Cell Bank | Cord blood | Switzerland | |
| China National GeneBank | Comprehensive | China | |
| National Stem Cell Resource Center | Comprehensive | China | |
| Shanghai East Hospital Biobank | Comprehensive | China | |
China Stem Cell Group Boyalife | Cord blood Cord blood | China China |
Fig. 1Basic principles of “5C” for the establishment of a modern stem cell bank
Internationally approved stem cell drugs
| Year | Corporation | Stem cell type | Clinical application | Name of bank |
|---|---|---|---|---|
| 2009.12 | Prochymal/Osiris Therapeutics, Inc., USA | Mesenchymal stem cells from human allogeneic bone marrow | Graft versus host disease (GVHD) and Crohn’s disease | American Food and Drug Administration (FDA) |
| 2010.07 | MPC/Mesoblast | Autologous mesenchymal precursor cells | Bone reconstruction | Production permit of Therapeutic Goods Administration (TGA) in Australia |
| 2011.07 | Hearticellgram-AMI/FCB-Pharmicell | Autologous bone marrow mesenchymal stem cells | Acute myocardial infarction | Food and Drug Administration in South Korea |
| 2011.11 | Hemacord/New York Blood Center | Cord blood hematopoietic progenitor cells | Hereditary or acquired hematopoietic disease | Biological License of American Food and Drug Administration (FDA) |
| 2011.11 | MultiStem/Athersys Inc., USA | Allogeneic bone marrow stem cell | Type I mucopolysaccharidosis | American Food and Drug Administration (FDA) |
| 2012.01 | Cartistem/Medi-post | Mesenchymal stem cells from the cord blood | Degenerative arthritis and cartilage damage in the knee joint | Food and Drug Administration in South Korea |
| 2012.01 | Cuepistem/Anterogen | Mesenchymal stem cells from autologous fat | Crohn’s disease complicating anal fistula | Food and Drug Administration in South Korea |